Abstract
There is paucity of data in pediatric Acute Myeloid Leukemia (AML) from developing countries. We analyzed the outcomes of 65 consecutive patients with pediatric AML treated at our centre from January-2008 to May-2013. The median event free survival (EFS) and overall survival (OS) were 12.6 and 14.6 months respectively. Patients with good-risk cytogenetics had a better EFS (p = 0.004) and OS (p = 0.01). Overall, these results are not comparable to that observed in other centres globally and leaves scope for further improvement. This includes implementing allogeneic bone marrow transplantation as a treatment for all children with high-risk AML.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Creutzig U, Zimmermann M, Ritter J et al (2005) Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 19:2030–2042
Smith FO, Alonzo TA, Gerbing RB et al (2005) Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children’s Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 19:2054–2062
Kulkarni KP, Marwaha RK (2011) Childhood acute myeloid leukemia: an Indian perspective. Pediatr Hematol Oncol 28:257–268
Manola KN (2009) Cytogenetics of pediatric acute myeloid leukemia. Eur J Haematol 83:391–405
Common Toxicity Criteria for Adverse Events v4.0 (CTCAE). http://evs.nci.nih. gov/ftp1/CTCAE/About.html; Accessed 15 Oct 2014
Bakhshi S, Singh P, Swaroop C (2009) Outpatient consolidation chemotherapy in pediatric acute myeloid leukemia: a retrospective analysis. Hematology 14:255–260
Kavcic M, Fisher BT, Li Y, Seif AE, Torp K, Walker DM, Huang YS, Lee GE, Tasian SK, Vujkovic M, Bagatell R, Aplenc R (2013) Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States. Cancer 119:1916–1923
Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T (2004) Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 22:4384–4393
Kardos G, Zwaan CM, Kaspers GJ et al (2005) Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia 19:2063–2071
Jain M, Bakhshi S, Shukla AA et al (2010) Cathepsins B and L in peripheral blood mononuclear cells of pediatric acute myeloid leukemia: potential poor prognostic markers. Ann Hematol 89:1223–1232
Sharawat SK, Bakhshi R, Vishnubhatla S et al (2010) Mitochondrial D-loop variations in paediatric acute myeloid leukaemia: a potential prognostic marker. Br J Haematol 149:391–398
Mukhopadhyay S, Chitalkar P, Mukhopadhyay A (2007) Oral chemotherapeutic agents in paediatric acute myeloid leukemia (AML) patients, a study from developing country [abstract]. Pediatr Blood Cancer 49:528
Banavali SD, Biswas G, Nair CN et al (2004) PRET: an effective oral protocol for out-patient therapy in patients with acute myeloid leukemia (AML) [abstract]. Pediatr Blood Cancer 43:355
Trehan A, Mehra S, Gupta D et al (2008) Outcome in children with acute myeloid leukemia in a tertiary centre in North India [abstract]. Pediatr Blood Cancer. doi:10.1002/pbc
Borker A, Ambulkar I, Goyal S et al (2009) Pediatric acute myeloid leukemia: single center experience [abstract]. Pediatr Blood Cancer 53:781
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Rights and permissions
About this article
Cite this article
Radhakrishnan, V., Thampy, C., Ganesan, P. et al. Acute Myeloid Leukemia in Children: Experience from Tertiary Cancer Centre in India. Indian J Hematol Blood Transfus 32, 257–261 (2016). https://doi.org/10.1007/s12288-015-0591-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-015-0591-5